Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Dec 06, 2021 11:18am
90 Views
Post# 34202209

RE:RE:RE:RE:RE:RE:RE:RE:RE:Options

RE:RE:RE:RE:RE:RE:RE:RE:RE:Options It appears so, and it's a bit disappointing. The only salve we can take from this is twofold, and I think we shouldn't blow this out of proportion and stay focused on the most meaningful milestone we need to see.  i know there's an undercurrent of being pi$$ed off, but this may help.

1.  In reality, the share hung around the US$3.50 level for a long, long time.  If we assume that was a less tax-selling-influenced level in and would likely have been the fair level strike price at this time, then the difference is around 15%.  Now, the negative could be what it trades at in Feb when they would have normally issued these.  We may feel a bit more resentment then, but as of now it's not that far off "fair market" as the market was trading without distortions.

2. They now all have a much bigger incentive to see it move far beyond US$3.00 if they want these options to be worth somethiing substantial. That should focus the mind even more on how to see what they do translated in to share price appreciation --something we are long overdue.

They really should have bought a lot more insider shares after the last call and that would have been a far better indication to shareholders.  While I will be happy if come February the share is above $5, there will be a little head-shaking as to why they all didn't buy in November and grant options in Feb.  We'll see.


longterm56 wrote: Well, now we know why there is minimal inside buying! No need to buy when you get a windfall of option grants! -LT
palinc2000 wrote:

Let me put it another way
It appears they want to grant options before the exercise price goes higher
I think it is all legal

 

ANALIAS00 wrote: That would be considered as 'deli d'initi' in my opinion



palinc2000]So it appears that they have NOT been trying to prop up the share price  to get a lower exercise price on the options .....sickening sickening sickening !!!! Hard to accept quotethat Paul would be playing such game ,,,,I hope I am reading this wrong

 

 

SABBOBCAT wrote: I commented a while back (or meant to) about how they were dragging this out so they could keep the price low and grant a bunch of options... I was talking March, not December. I am excited because it signals something material must be coming shortly, but I am appalled by the blatant exploitation of shareholders.

They know shareholders were pissed after the OO and are now frustrated by the lack of communication and low share price, so that do they do? "Hey let's grant ourselves a ton of options 3 days into the new fiscal year (3-4 months earlier than normal) to pad our already generous options comp before finally releasing positive news”. This makes me sick as a shareholder that has seen nothing by disregard from management and IR over the last few years. It looks super GREASY and management should be ashamed.
 

 




[/quote]

<< Previous
Bullboard Posts
Next >>